Hyaluronic Acid
Extensive preclinical studies, including in vitro and animal models, have demonstrated that hyaluronic acid promotes anabolic activity, supporting cartilage synthesis while inhibiting processes that contribute to cartilage degradation.
In clinical settings, hyaluronic acid exerts well-documented anti-inflammatory and analgesic effects. Research continues to optimize its use and better understand its mechanisms in joint health.
As a fundamental component of synovial fluid, hyaluronic acid plays a crucial role in maintaining joint function by protecting cartilage from mechanical stress and wear associated with daily activities.
Hyaluronic acid viscosupplementation is a well-established and widely utilized treatment for osteoarthritis. Robust clinical evidence on viscosupplementation confirms its efficacy in reducing osteoarthritis symptoms, with a favorable safety profile compared to NSAIDs and corticosteroids. Recent studies have further supported its use in patients with mild to moderate osteoarthritis, including younger individuals at higher risk of disease progression.
Therapeutic Possibilities
Hyaluronic acid formulations vary based on molecular weight, origin, and dosage. Early preparations required multiple injections to achieve a sustained therapeutic effect. To reduce the number of treatment sessions, cross-linked hyaluronic acid products were developed, enabling single-injection regimens; however, these formulations have been associated with a higher incidence of adverse effects.
Currently, high and medium molecular weight hyaluronic acid preparations are the most commonly utilized, supported by clinical evidence demonstrating superior efficacy in pain relief and improved joint function compared to low molecular weight and cross-linked variants.
Adverse effects are infrequent and typically limited to localized swelling and/or erythema at the injection site, which can be effectively managed with ice application and, if necessary, paracetamol.
Importantly, hyaluronic acid exhibits no known drug interactions, underscoring its safety profile in diverse patient populations.
Types of Hyaluronic Acid
In the management of cartilage degeneration, we employ advanced formulations of next-generation hyaluronic acid. The first formulation consists of a medium molecular weight hyaluronic acid blend, administered as a 100 mg dose through three injections spaced 15 to 20 days apart.
This blend primarily contains high molecular weight hyaluronic acid (1200–1500 kDa), which is highly effective for viscosupplementation, complemented by a smaller proportion of low molecular weight hyaluronic acid (200–400 kDa), known for its capacity to mitigate joint damage associated with osteoarthritis.
Additionally, this formulation includes trehalose, a specialized excipient that protects hyaluronic acid from enzymatic degradation, thereby prolonging its therapeutic effect.
The second formulation features a high molecular weight hyaluronic acid at a concentration of 2%, resulting in a highly viscous product. This preparation is further enhanced with niacinamide, an antioxidant that protects against hyaluronidase activity, extending the duration and efficacy of the treatment at the injection site.
Furthermore, several studies support the combined use of hyaluronic acid with platelet-rich plasma (PRP). This synergistic approach leverages the lubricating properties of hyaluronic acid alongside the regenerative potential of PRP, which, through its abundant growth factors, promotes tissue repair and healing in damaged joints.


